Robust Central Reduction of Amyloid-  in Humans with an Orally Available, Non-Peptidic  -Secretase Inhibitor by May, P. C., Dean, R. A., Lowe, S. L., Martenyi, F., Sheehan, S. M., Boggs, L. N., Monk, S. A., Mathes, B. M., Mergott, D. J., Watson, B. M., Stout, S. L., Timm, D. E., Smith LaBell, E., Gonzales, C. R., Nakano, M., Jhee, S. S., Yen, M., Ereshefsky, L., Lindstrom, T. D., Calligaro, D. O., Cocke, P. J., Greg Hall, D., Friedrich, S., Citron, M., Audia, J. E.

Get full text

Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus by Aronson, Ronnie, Biester, Torben, Leohr, Jennifer, Pollom, Robyn, Linnebjerg, Helle, LaBell, Elizabeth Smith, Zhang, Qianyi, Coutant, David E., Danne, Thomas

Get full text

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor by May, Patrick C, Dean, Robert A, Lowe, Stephen L, Martenyi, Ferenc, Sheehan, Scott M, Boggs, Leonard N, Monk, Scott A, Mathes, Brian M, Mergott, Dustin J, Watson, Brian M, Stout, Stephanie L, Timm, David E, Smith Labell, Elizabeth, Gonzales, Celedon R, Nakano, Masako, Jhee, Stanford S, Yen, Mark, Ereshefsky, Larry, Lindstrom, Terry D, Calligaro, David O, Cocke, Patrick J, Greg Hall, D, Friedrich, Stuart, Citron, Martin, Audia, James E

Get full text

Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects by Payne, Christopher D., Deeg, Mark A., Chan, Melanie, Tan, Lai Hock, LaBell, Elizabeth Smith, Shen, Tong, DeBrota, David J.

Get full text

Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects by Linnebjerg, Helle, LaBell, Elizabeth Smith, Dellva, Mary Anne, Coutant, David E., Leohr, Jennifer

Get full text